HC Wainwright Predicts PepGen’s Q2 Earnings (NASDAQ:PEPG)

PepGen, Inc. (NASDAQ:PEPG) – Investment analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for PepGen in a research note issued to investors on Wednesday, May 13th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of ($0.27). The consensus estimate for PepGen’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for PepGen’s Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($1.79) EPS, FY2028 earnings at ($1.73) EPS, FY2029 earnings at ($1.34) EPS and FY2030 earnings at ($0.57) EPS.

PepGen (NASDAQ:PEPG) last announced its earnings results on Tuesday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05.

Several other brokerages have also issued reports on PEPG. Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a research report on Tuesday, April 21st. Oppenheimer initiated coverage on PepGen in a research report on Wednesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. Guggenheim boosted their price target on PepGen from $6.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Wedbush lowered their price target on PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a report on Wednesday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

PepGen Price Performance

Shares of NASDAQ:PEPG opened at $1.65 on Friday. PepGen has a 1 year low of $1.01 and a 1 year high of $7.80. The business has a 50 day simple moving average of $3.06 and a two-hundred day simple moving average of $4.71. The firm has a market capitalization of $114.13 million, a PE ratio of -0.94 and a beta of 2.01.

Institutional Trading of PepGen

Large investors have recently modified their holdings of the company. Heights Capital Management Inc. purchased a new stake in shares of PepGen in the third quarter valued at approximately $46,000. Burkehill Global Management LP purchased a new stake in shares of PepGen in the third quarter valued at approximately $46,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of PepGen by 94.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock valued at $73,000 after purchasing an additional 5,453 shares during the period. Jefferies Financial Group Inc. purchased a new stake in shares of PepGen in the fourth quarter valued at approximately $89,000. Finally, Militia Capital Partners LP purchased a new stake in shares of PepGen in the third quarter valued at approximately $72,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).